| John E. Friend |
John E. Friend is currently the Chief Executive Officer at Kazia Therapeutics Ltd. Prior to his current position, he served as the Senior Vice President-Medical & Scientific Affairs at Helsinn Therapeutics (U.S.), Inc. from 2010 to 2017. He then worked as the Chief Medical Officer & Vice President at Cellectar Biosciences, Inc. from 2017 to 2018, and again from 2020 to 2021. Additionally, he held the position of Chief Medical Officer at Druggability Technologies Holdings Ltd. (New Jersey). Dr. Friend obtained his undergraduate degree from Southern Methodist University and his doctorate from Robert Wood Johnson Medical School. |
| Bryce D. Carmine |
Bryce D. Carmine is currently the Chairman at Kazia Therapeutics Ltd. since 2015 and at HaemaLogiX Pty Ltd. since 2015. Previously, he served as the Chairman at Eli Lilly Australia Pty Ltd. from 1989 to 1995. He also held the position of Director at ImClone LLC. Additionally, he worked at Eli Lilly & Co. from 1983 to 2012, where he served as the Executive Vice President in 2011. From 1995 to 1999, he was the President & General Manager at Eli Lilly Japan KK. He also held the position of General Manager at Daewoong-Lilly Pharmaceutical Co. Mr. Carmine completed his undergraduate degree at Massey University in 1973. |
| Karen R. Krumeich |
Karen R. Krumeich is currently the Chief Financial Officer at Kazia Therapeutics Ltd. She previously held the same position at Soligenix, Inc., Aksys Ltd., and STRATA Skin Sciences, Inc. She was also a Partner at Tatum LLC and Vice President-Finance at Avalo Therapeutics, Inc. Additionally, she served as Vice President-Finance at Gran Care Pharmacy, Inc. and was a Member of the National Healthcare Group. Ms. Krumeich holds an undergraduate degree from the University of Toledo (Ohio). |
